Clinical trial NCT03498742: Asthmatic Subjects Could Live Without Short Acting beta2 Agonists
Official title: Asthmatic Subjects Could Live Without Short Acting Beta2 Agonists (SABA)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma Chronic
Keywords: asthma
SABA
Lead sponsor: Universidad Nacional de Rosario
Sponsor class: OTHER
First posted: 2018-04-17
Enrollment: 86
Sex: ALL
Minimum age (years): 16
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Outpatients coming for a first visit to the Pulmonary Section, not only due to asthma; but also for presurgical assessment and/or Spirometry prescription.

Brief summary: Since 2006 there was a plateau in world wide mortality from asthma. Overreliance in Short Acting Beta2 Agonists (SABA) was associated with increased risk of death from asthma. Long acting beta agonists (LABA) alone was not permitted as treatment for asthma as it was determined by FDA by the "black box". By contrast SABA does not have a "black box", despite similar overuse alerts associated with increased risk of death from asthma. the investigators want to know if exist asthmatic subjects that do use another rescue medication; not SABA, and to compare their features, Asthma Control Test (ACT), and lung function in a outpatient facility.

First consecutive visits at outpatient Pulmonary Section of asthmatic subjects were described. Asthma Control Test (ACT) that was routinely used to assess asthma and spirometry were performed.

Detailed description: During the period from March 10, 2017 to January 16, 2018 the investigators decided to describe the rescue medication in all new asthmatic subjects that came for a first visit to the outpatient pulmonary department. Patients aged ≥16 years were entered in the study with a a diagnosis of asthma, based on a history of episodic dyspnea and wheezing, and/or documented bronchodilator reversibility in forced expiratory volume in 1 s (FEV1) of 12% and 200 ml according to the National Institutes of Health criteria; to be non- or ex-smoker of less than 10 pack-yr, to be neither pregnant nor breast-feeding and to be capable of completing Asthma control test and spirometry. Consecutive patients visiting the outpatient pulmonary department were included in the description.

Eligibility criteria: Inclusion Criteria:

1. diagnosis of asthma, based on a history of episodic dyspnea and wheezing, and/or documented bronchodilator reversibility in forced expiratory volume in 1 s (FEV1) of 12% and 200 ml according to the National Institutes of Health criteria;
2. to be non- or ex-smoker of less than 10 pack-yr,
3. to be neither pregnant nor breast-feeding
4. to be capable of completing Asthma control test and spirometry. -

Exclusion Criteria:

Any other pulmonary disorder than asthma. Illiteracy.

-

Primary outcomes:
measure: Asthma Control Test
timeFrame: One year
Secondary outcomes:
measure: Acute asthma attack requiring Hospitalization and/or Emergency Room visits in the last 12 months
timeFrame: One year
Other outcomes:
Locations:
city: Granadero Baigorria
country: Argentina
facility: Pulmonary Section
state: Santa Fe
Study officials:
affiliation: Universidad Nacional de Rosario
name: Luis J Nannini, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nannini LJ, Neumayer NS. Treatment Step 1 for Asthma Should Not Be Left Blank, and SABA-Only Might Not Be a Treatment Step 1 Option for Asthma. Respiration. 2018;95(3):212-214. doi: 10.1159/000484568. Epub 2017 Dec 14. No abstract available.
citation: Rodrigo GJ, Arcos JP, Nannini LJ, Neffen H, Broin MG, Contrera M, Pineyro L. Reliability and factor analysis of the Spanish version of the asthma control test. Ann Allergy Asthma Immunol. 2008 Jan;100(1):17-22. doi: 10.1016/S1081-1206(10)60399-7.